Medtronic, Parkinson's and FDA

In Parkinson’s fight, Medtronic’s first-in-the-world adaptive therapy feature wins FDA approval
After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive technology personalizing treatment of Parkinson’s symptoms using advanced stimulation deep in the brain.
US FDA approves Medtronic's medical device for Parkinson's disease
The U.S. Food and Drug Administration has approved Medtronic's deep brain stimulation system for use in patients with Parkinson's disease, the medical device maker said on Monday.
Medtronic earns U.S. FDA approval for the world's first Adaptive deep brain stimulation system for people with Parkinson's
For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug Administration (FDA) approval of BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™
Medtronic gets FDA approval for Brainsense device in Parkinson's patients
Medtronic said Monday the U.S. Food and Drug Administration has approved an adaptive brain-stimulation device as a treatment for people with Parkinson's disease, a major milestone for the technology.
FDA approves first adaptive deep brain stimulation system for Parkinson’s disease
The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in real time based on the patient’s brain activity, according to the manufacturer.
Medtronic’s BrainSense brain stimulation system approved by FDA for Parkinson’s
Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no
Medtronic gains FDA OK for self-adjusting DBS system for Parkinson’s
Medtronic received Food and Drug Administration approval for the BrainSense Adaptive deep brain stimulation (DBS) device for people with Parkinson’s disease, a movement disorder of the nervous system.
FDA OKs First Adaptive DBS System for Parkinson’s Disease
The closed-loop system dynamically self-adjusts DBS therapy to individual brain activity in real time, providing personalized neuromodulation that responds to the patient’s changing needs.
FDA Approves Medtronic's Adaptive Deep Brain Stimulation System For Parkinson's Patients
The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy personalization and clinic efficiency.
U.S. Deep Brain Stimulation In Parkinson's Disease Market Research 2025-2030 with Competitive Analysis of ABBOTT, Medtronic, and Boston Scientific
The "U.S. Deep Brain Stimulation In Parkinson's Disease Market Size, Share & Trends Analysis Report By Product (Single-channel, Dual-channel), Competitive Analysis, And Segment Forecasts, 2025 - 2030" report has been added to ResearchAndMarkets.
FDA approves Medtronic device for Parkinson's treatment
The FDA has approved Medtronic's Brainsense Adaptive deep brain stimulation for patients with Parkinson's disease. The technology is designed to adjust therapy in real time based on a patient's brain activity,
Medical Design and Outsourcing19h
A Medtronic engineer shares lessons from the adaptive deep brain stimulation project
The biggest technical challenge for adaptive deep brain stimulation (aDBS) is how small brain signals are, Medtronic's Scott ...
Parkinson’s Patients Now Have a New Way to Manage Symptoms
There is still no cure for Parkinson’s disease, but the U.S. Food and Drug Administration (FDA) approved a new deep brain ...